- Home
- CTMX
as 05-14-2025 4:00pm EST
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 60.7M | IPO Year: | 2015 |
| Target Price: | $2.50 | AVG Volume (30 days): | 9.5M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.49 | EPS Growth: | 128.27 |
| 52 Week Low/High: | $0.40 - $2.81 | Next Earning Date: | 05-12-2025 |
| Revenue: | $147,557,000 | Revenue Growth: | 23.81% |
| Revenue Growth (this year): | -26.71% | Revenue Growth (next year): | -70.54% |
Stock Insider Trading Activity of CytomX Therapeutics Inc. (CTMX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CTMX | CEO | Mar 18 '25 | Sell | $0.60 | 37,656 | $22,555.94 | 995,195 | |
| ROWLAND LLOYD A | CTMX | General Counsel | Mar 18 '25 | Sell | $0.60 | 10,203 | $6,111.60 | 120,594 | |
| Ogden Christopher | CTMX | Chief Financial Officer | Mar 18 '25 | Sell | $0.60 | 8,551 | $5,122.05 | 201,026 | |
| BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Mar 18 '25 | Sell | $0.60 | 19,512 | $11,687.69 | 248,636 | |
| Chu Yu-Waye | CTMX | Chief Medical Officer | Mar 18 '25 | Sell | $0.60 | 4,025 | $2,410.98 | 135,725 |
Latest CytomX Therapeutics Inc. News
CTMX Breaking Stock News: Dive into CTMX Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
2 days ago
Q1 2025 CytomX Therapeutics Inc Earnings Call
MT Newswires
3 days ago
CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data
MT Newswires
3 days ago
Wedbush Adjusts CytomX Therapeutics Price Target to $6 From $5, Maintains Outperform Rating
MT Newswires
3 days ago
Top Premarket Gainers
Zacks
3 days ago
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
GlobeNewswire
3 days ago
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
Associated Press Finance
3 days ago
CytomX Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
3 days ago
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
Compare CTMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTMX CytomX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.